# Liquid Biopsy for Early Pancreatic Cancer Detection: Why Has It Not Yet Worked?

## TL;DR

Liquid biopsy has not yet succeeded in early detection of pancreatic cancer due to biological and technical challenges, despite technological advances.

## Contribution

The paper critically examines the biological and technical barriers to liquid biopsy for early pancreatic cancer detection and proposes potential solutions.

## Key findings

- Early pancreatic cancer and precursor lesions have minimal tumor burden and low nucleic acid shedding.
- Multilayered liquid biopsy approaches have not consistently improved diagnostic performance.
- Pre-analytical variability and lack of standardization hinder clinical implementation.

## Abstract

Liquid biopsy is anticipated as a non-invasive complement to histopathology, yet its utility for early detection of pancreatic ductal adenocarcinoma (PDA) remains limited. The primary obstacles are biological—specifically minimal tumor shedding—rather than purely technical, hindering clinical implementation. We critically examine these barriers and the lack of standardization. Furthermore, we outline potential solutions and initiatives to overcome these challenges, incorporating our own clinical attempts and experimental data to bridge the gap toward meaningful clinical application.

Despite extensive technological advances and an ever-growing body of literature, liquid biopsy has yet to achieve reliable early detection of pancreatic ductal adenocarcinoma (PDA). Numerous studies have investigated circulating tumor-derived components, including cell-free DNA (cfDNA), cell-free RNA (cfRNA), extracellular vesicles (EVs), and circulating tumor cells (CTCs), primarily using peripheral blood samples; however, their clinical utility for early-stage disease remains limited. The fundamental obstacles are biological rather than purely technical: early PDA and its precursor lesions, such as pancreatic intraepithelial neoplasia (PanIN) and intraductal papillary mucinous neoplasms (IPMN), are characterized by minimal tumor burden, low levels of nucleic acid shedding, and substantial background signals from non-neoplastic tissues. Increasing analytical complexity through multilayered liquid biopsy approaches, including analyses from pancreas-associated fluid, has not consistently translated into improved diagnostic performance and, in some cases, has amplified issues related to specificity, reproducibility, and interpretability. Moreover, molecular alterations detected in body fluids may reflect clonal expansion without inevitable malignant progression, raising concerns regarding overdiagnosis and clinical decision-making. Pre-analytical variability, lack of standardization, and limited access to tumor-adjacent fluids further hinder clinical implementation. Liquid biopsy should therefore be regarded as a complementary modality rather than a substitute for histopathological diagnosis, with its precise clinical role in early detection still ill-defined. In this review, we critically examine why liquid biopsy has not yet succeeded in early PDA detection, highlighting the key biological, technical, and clinical barriers that must be addressed to move the field beyond exploratory research toward meaningful clinical application.